US 12,076,440 B2
Powder blend processability improvements through minimal amounts of synergistically selected surface coating agents
Rajesh N. Dave, Princeton, NJ (US); Sangah Kim, Newark, NJ (US); and Zhixing Lin, Newark, NJ (US)
Assigned to New Jersey Institute of Technology, Newark, NJ (US)
Filed by New Jersey Institute of Technology, Newark, NJ (US)
Filed on Jul. 12, 2023, as Appl. No. 18/221,143.
Claims priority of provisional application 63/388,422, filed on Jul. 12, 2022.
Prior Publication US 2024/0024241 A1, Jan. 25, 2024
Int. Cl. A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 31/192 (2006.01); A61K 45/06 (2006.01); B82Y 5/00 (2011.01); B82Y 30/00 (2011.01)
CPC A61K 9/143 (2013.01) [A61K 9/1682 (2013.01); A61K 31/192 (2013.01); A61K 45/06 (2013.01); B82Y 5/00 (2013.01); B82Y 30/00 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A pharmaceutical composition, comprising:
a plurality of fine cohesive powder components forming a pharmaceutical blend and each component having a particle size between 10-30 microns and a flow function coefficient (FFC) under 4 FFC prior to any surface modification or treatment, wherein at least one of the components is an active pharmaceutical ingredient (API);
the pharmaceutical blend further including:
a dry coated minority component dry coated with a nano-sized flow aid powder at about 0.1 microns (100 nanometers) or less in particle size; wherein the minority component is the only component dry coated or having any surface modification or treatment, the minority component further defined as one of the plurality of fine powder components having an amount of 0.1 wt % to about less than 5 wt %, based on the total weight of the pharmaceutical blend of all components weight, regardless of the minority component's individual component weight;
wherein the pharmaceutical blend is formed when only the dry coated minority component is mixed with a remainder of the fine cohesive powder components to form a flow aid concentration in the blend in a range of about 0.116 to 0.007 wt % and the blend surface area coverage (SAC) of about 0.1% to about 9% SAC;
wherein an actual FFC of the pharmaceutical blend is greater than 4 FFC and an expected and calculated FFC for the pharmaceutical blend and wherein the calculated FFC after dry coating is determined by using a weighted FFC average of the pharmaceutical blend having the plurality of fine cohesive powder components after dry coating the minority component and blending the components, and wherein the actual FFC is determined by testing the pharmaceutical blend after dry coating the minority component and blending the components; and
wherein improvement to the actual FFC of the pharmaceutical blend is not from the nano-sized flow aid powder but from the dry coated minority component when mixed in the pharmaceutical blend.